The Glimpse Group (VRAR) Q1 FY2026 revenue missed estimates, but its EPS loss was slightly better than expected. The company is focused on its Brightline Interactive spinoff and new government contracts.
AirJoule (AIRJ) stock rose after Q3 2025 results, beating EPS estimates with a smaller loss. The water-harvesting tech firm also announced key partnerships and progress toward 2026 commercialization.
Applied Materials (AMAT) narrowly beat Q4 FY2025 earnings and revenue estimates, achieving record annual results driven by AI and advanced semiconductor demand.
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.
Hyperfine (HYPR) reported mixed Q3 2025 results, missing revenue and EPS estimates. The stock fell as its Q4 revenue guidance also trailed analyst expectations.
Net Power stock fell 12% after a strategic pivot to carbon capture tech, overshadowing an accounting-driven EPS beat and revealing a major asset impairment.
HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
BioAtla (BCAB) beat Q3 2025 EPS estimates, sending its stock up 7.5%. The biotech also gained FDA alignment for its Phase 3 trial in head and neck cancer.
TELA Bio reports Q3 2025 results with 9% revenue growth to $20.7M, missing estimates. The company improved its net loss and secured new financing for future expansion.
Rekor Systems (REKR) smashed Q3 2025 estimates with record revenue of $14.2M and a smaller-than-expected loss, sparking a positive after-hours market reaction.
WidePoint's Q3 2025 earnings show a revenue miss but strong sequential profit growth. The company secured major new contracts and maintains a $269M backlog for future growth.
Cytosorbents Q3 2025 earnings show a mixed quarter, beating EPS estimates but missing on revenue. The stock saw volatility despite a strengthened balance sheet.
Evolv Technology (EVLV) crushed Q3 2025 earnings estimates, reporting a surprise profit and strong revenue growth. The company also raised its full-year guidance.
Cibus (CBUS) Q3 2025 results show a narrower loss but a revenue miss, sending shares lower. The company highlights progress on key rice traits and cost-saving initiatives.
Jefferson Capital (JCAP) beat Q3 2025 earnings and revenue estimates, driven by record collections and deployments. The company also announced a major acquisition.
Nu Holdings (NU) Q3 2025 earnings smashed revenue estimates, reporting $4.17B. Customer growth and profitability surged, driving a 39% YoY net income increase to $783M.
GBP/USD caught a brief bullish slant to Thursday’s trading window, with Cable traders brushing off a worse-than-expected GDP growth print from the third quarter.
Luminar (LAZR) Q3 2025 earnings beat revenue and EPS estimates, sending shares up 14%. The company is exploring strategic alternatives amid significant losses.
Origin Materials Q3 2025 results missed revenue and EPS estimates, causing a negative market reaction. The company maintains its long-term growth targets.
The company currently offers a high dividend yield of about 8%, backed by a consistent track record of dividend growth and a “Strong Buy” consensus from Wall Street analysts.
Join us as we dissect SentinelOne's stock performance and future potential in the competitive cybersecurity landscape. Can its new AI product turn the tide?
A mass de-risking ritual the street performs whenever liquidity thins, uncertainty thickens, and everyone wants to pretend they’re early rather than late.
